[1] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J]. CA Cancer J Clin,2017,67(1):7-30.
[2] Shi S, Hua J, Liang C, et al.Proposed modification of the 8th Edition of the AJCC Staging System for pancreatic ductal adenocarcinoma[J]. Ann Surg,2019,269(5):944-950.
[3] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin,2016,66(2):115-132.
[4] Rahib L, Smith BD, Aizenberg R, et al.Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States[J]. Cancer Res,2014,74(11):2913-2921.
[5] Tol JA, Gouma DJ, Bassi C, et al.Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery(ISGPS)[J]. Surgery,2014,156(3):591-600.
[6] Jang JY, Kang JS, Han Y, et al.Long-term outcomes and recurrence patterns of standard versus extended pancreatectomy for pancreatic head cancer: a multicenter prospective randomized controlled study[J]. J Hepatobi-liary Pancreat Sci,2017,24(7):426-433.
[7] Jang JY, Kang MJ, Heo JS, et al.A prospective rando-mized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer[J]. Ann Surg,2014,259(4):656-664.
[8] Borghi F, Gattolin A, Garbossa D, et al.Embryologic bases of extended radical resection in pancreatic cancer[J]. Arch Surg,1998,133(3):297-301.
[9] Jennings RE, Berry AA, Strutt JP, et al.Human pancreas development[J]. Development,2015,142(18):3126-3137.
[10] Cesmebasi A, Malefant J, Patel SD, et al.The surgical anatomy of the lymphatic system of the pancreas[J]. Clin Anat,2015,28(4):527-537.
[11] Kanda M, Fujii T, Nagai S, et al.Pattern of lymph node metastasis spread in pancreatic cancer[J]. Pancreas,2011, 40(6):951-955.
[12] Nagakawa T, Kobayashi H, Ueno K, et al.Clinical study of lymphatic flow to the paraaortic lymph nodes in carcinoma of the head of the pancreas[J]. Cancer,1994,73(4):1155-1162.
[13] Nagakawa T, Konishi I, Ueno K, et al.A clinical study on lymphatic flow in carcinoma of the pancreatic head area--peripancreatic regional lymph node grouping[J]. Hepatogastroenterology,1993,40(5):457-462.
[14] Hirono S, Tani M, Kawai M, et al.Identification of the lymphatic drainage pathways from the pancreatic head guided by indocyanine green fluorescence imaging during pancreaticoduodenectomy[J]. Dig Surg,2012,29(2):132-139.
[15] Roche CJ, Hughes ML, Garvey CJ, et al.CT and pathologic assessment of prospective nodal staging in patients with ductal adenocarcinoma of the head of the pancreas[J]. Am J Roentgenol,2003,180(2):475-480.
[16] Imai H, Doi R, Kanazawa H, et al. Preoperative assessment of para-aortic lymph node metastasis in patients with pancreatic cancer[J]. Int J Clin Oncol,2010,15(3):294-300.
[17] Kumon RE, Pollack MJ, Faulx AL, et al., In vivo characterization of pancreatic and lymph node tissue by using EUS spectrum analysis: a validation study[J]. Gastrointest Endosc,2010,71(1):53-63.
[18] Kurita A, Kodama Y, Nakamoto Y, et al.Impact of EUS-FNA for preoperative para-aortic lymph node staging in patients with pancreatobiliary cancer[J]. Gastrointest Endosc,2016,84(3):467-475 e1.
[19] Kalogeraki A, Papadakis GZ, Tamiolakis D, et al.EUS-fine-needle aspiration biopsy(FNAB) in the diagnosis of pancreatic adenocarcinoma: a review[J]. Rom J Intern Med,2016,54(1):24-30.
[20] Nathanson SD, Shah R, Rosso K.Sentinel lymph node metastases in cancer: causes, detection and their role in disease progression[J]. Semin Cell Dev Biol,2015,38:106-116.
[21] John BJ, Naik P, Ironside A, et al.Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph nodal burden and lymph node ratio are the only prognostic factors associated with survival[J]. HPB (Oxford),2013,15(9):674-680.
[22] Aoyama T, Yamamoto N, Kamiya M, et al.The lymph node ratio is an independent prognostic factor in pancrea-tic cancer patients who receive curative resection followed by adjuvant chemotherapy[J]. Anticancer Res,2018,38(8):4877-4882.
[23] Yamada S, Fujii T, Hirakawa A, et al.Lymph node ratio as parameter of regional lymph node involvement in pancreatic cancer[J]. Langenbecks Arch Surg,2016,401(8):1143-1152.
[24] Chen JW, Bhandari M, Astill DS, et al.Predicting patient survival after pancreaticoduodenectomy for malignancy: histopathological criteria based on perineural infiltration and lymphovascular invasion[J]. HPB (Oxford),2010,12(2):101-108.
[25] Marmor S, Burke EE, Portschy PR, et al.Lymph node evaluation for treatment of adenocarcinoma of the pancreas[J]. Surg Oncol,2015,24(3):284-291.
[26] Kat’uchová J, Bober J, Kat’uch V, et al.Significance of lymph node micrometastasis in pancreatic cancer patients[J]. Eur Surg Res,2012,48(1):10-15.
[27] Jiang Y, Du Z, Yang F, et al.FOXP3+ lymphocyte density in pancreatic cancer correlates with lymph node metastasis[J]. PLoS One,2014,9(9):e106741.
[28] Schwarz L, Lupinacci RM, Svrcek M, et al.Para-aortic lymph node sampling in pancreatic head adenocarcinoma[J]. Br J Surg,2014,101(5):530-538.
[29] Robinson SM, Rahman A, Haugk B, et al.Metastatic lymph node ratio as an important prognostic factor in pancreatic ductal adenocarcinoma[J]. Eur J Surg Oncol,2012,38(4):333-339.
[30] Liu Z, Luo G, Guo M, et al.Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer[J]. Pancreatology,2015, 15(3):253-258.
[31] Konstantinidis IT, Deshpande V, Zheng H, et al.Does the mechanism of lymph node invasion affect survival in patients with pancreatic ductal adenocarcinoma?[J]. J Gastrointest Surg,2010,14(2):261-267.
[32] Buc E, Couvelard A, Kwiatkowski F, et al.Adenocarcinoma of the pancreas: Does prognosis depend on mode of lymph node invasion?[J]. Eur J Surg Oncol,2014,40(11):1578-1585.
[33] Pai RK, Beck AH, Mitchem J, et al.Pattern of lymph node involvement and prognosis in pancreatic adenocarcinoma: direct lymph node invasion has similar survival to node-negative disease[J]. Am J Surg Pathol,2011,35(2):228-234.
[34] Wang Z, Wu J, Li G, et al.Lymphangiogenesis and biological behavior in pancreatic carcinoma and other pancreatic tumors[J]. Mol Med Rep,2012,5(4):959-963.
35] Von Marschall Z, Scholz A, Stacker SA, et al. Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer[J]. Int J Oncol,2005,27(3):669-679.
[36] Zorgetto VA, Silveira GG, Oliveira-Costa JP, et al.The relationship between lymphatic vascular density and vascular endothelial growth factor A(VEGF-A) expression with clinical-pathological features and survival in pancrea-tic adenocarcinomas[J]. Diagn Pathol,2013,8:170.
[37] Sipos B, Kojima M, Tiemann K, et al.Lymphatic spread of ductal pancreatic adenocarcinoma is independent of lymphangiogenesis[J]. J Pathol,2005,207(3):301-312.
[38] Schneider M, Buchler P, Giese N, et al.Role of lymphangiogenesis and lymphangiogenic factors during pancreatic cancer progression and lymphatic spread[J]. Int J Oncol,2006,28(4):883-890.
[39] Feig C, Gopinathan A, Neesse A, et al.The pancreas cancer microenvironment[J]. Clin Cancer Res,2012,18(16):4266-4276.
[40] Olszewski WL, Stanczyk M, Gewartowska M, et al.Lack of functioning intratumoral lymphatics in colon and pancreas cancer tissue[J]. Lymphat Res Biol,2012,10(3):112-117.
[41] Padera TP, Kadambi A, di Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics[J]. Science,2002,296(5574):1883-1886.
[42] He Y, Rajantie I, Pajusola K, et al.Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels[J]. Cancer Res,2005,65(11):4739-4746.
[43] Padera TP, Kuo AH, Hoshida T, et al.Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib[J]. Mol Cancer Ther,2008,7(8):2272-2279.
[44] Hoshida T, Isaka N, Hagendoorn J, et al.Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing deli-very of cancer cells to lymph nodes: therapeutic implications[J]. Cancer Res,2006,66(16):8065-8075.
[45] Singh I, Swami R, Khan W, et al.Lymphatic system: a prospective area for advanced targeting of particulate drug carriers[J]. Expert Opin Drug Deliv,2014,11(2):211-229.
[46] Ali Khan A, Mudassir J, Mohtar N, et al.Advanced drug delivery to the lymphatic system: lipid-based nanoformulations[J]. Int J Nanomedicine,2013,8:2733-2744.
[47] Kaminskas LM, Ascher DB, McLeod VM, et al. PEGylation of interferon alpha2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases[J]. J Control Release,2013,168(2):200-208.
[48] Li X, Dong Q, Yan Z, et al.MPEG-DSPE polymeric micelle for translymphatic chemotherapy of lymph node metastasis[J]. Int J Pharm,2015,487(1-2):8-16.
[49] Dunne AA, Boerner HG, Kukula H, et al.Block copolymer carrier systems for translymphatic chemotherapy of lymph node metastases[J]. Anticancer Res,2007,27(6B):3935-3940.
[50] Yang F, Jin C, Yang D, et al.Magnetic functionalised carbon nanotubes as drug vehicles for cancer lymph node metastasis treatment[J]. Eur J Cancer,2011,47(12):1873-1882.
